Starling Oncology annual depreciation and amortization
2020
2021
2022
2023
2024
2025
Starling Oncology Depreciation & Amortization Growth & History (STLN)
Starling Oncology's depreciation and amortization was $6.9M for fiscal 2025.
View full Starling Oncology company overviewStarling Oncology annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.9M | $657,000 | +10.45% |
| 2024 | 2024-12-31 | $6.3M | $414,000 | +7.05% |
| 2023 | 2023-12-31 | $5.9M | $1.5M | +33.14% |
| 2022 | 2022-12-31 | $4.4M | $1.1M | +32.03% |
| 2021 | 2021-12-31 | $3.3M | $163,000 | +5.13% |
| 2020 | 2020-12-31 | $3.2M | — | — |
Starling Oncology quarterly depreciation and amortization
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.8M | $33,000 | +1.83% |
| Q1 2026 | 2026-03-31 | $1.6M | −$168,000 | −9.42% |
| Q4 2025 | 2025-12-31 | $1.6M | — | — |
| Q3 2025 | 2025-09-30 | $1.7M | $150,000 | +9.54% |
| Q2 2025 | 2025-06-30 | $1.8M | $287,000 | +18.91% |
| Q1 2025 | 2025-03-31 | $1.8M | $295,000 | +19.81% |
| Q3 2024 | 2024-09-30 | $1.6M | −$125,000 | −7.36% |
| Q2 2024 | 2024-06-30 | $1.5M | $189,000 | +14.22% |
| Q1 2024 | 2024-03-31 | $1.5M | $220,000 | +17.34% |
| Q3 2023 | 2023-09-30 | $1.7M | $564,000 | +49.74% |
| Q2 2023 | 2023-06-30 | $1.3M | $231,000 | +21.04% |
| Q1 2023 | 2023-03-31 | $1.3M | $282,000 | +28.57% |
| Q3 2022 | 2022-09-30 | $1.1M | $284,000 | +33.41% |
| Q2 2022 | 2022-06-30 | $1.1M | $304,000 | +38.29% |
| Q1 2022 | 2022-03-31 | $987,000 | $210,000 | +27.03% |
| Q3 2021 | 2021-09-30 | $850,000 | — | — |
| Q2 2021 | 2021-06-30 | $794,000 | — | — |
| Q1 2021 | 2021-03-31 | $777,000 | — | — |
Starling Oncology depreciation and amortization trends
Over the last five fiscal years, Starling Oncology's depreciation and amortization increased from $3.2M to $6.9M, a change of $3.8M. The latest reported quarter, Q2 2026, shows $1.8M.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Starling Oncology source filings ↗